A Phase 2, Multicenter, Single-arm, Open-label Study in Japan to Evaluate the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2016
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Mar 2015 Planned End Date changed from 1 Dec 2019 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 21 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Sep 2014 as reported by ClinicalTrials.gov record.